Quarter
Charts

BioLife Solutions, Inc.

BLFS

CIK 0000834365 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$19M
Operating Income
$47M
Net Income
$46M
Gross Profit
$19M

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
34/100
  • Profitability
    0ROIC -3.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.94 (above 1.5 = solid)
  • Leverage
    99D/E 0.01 (under 0.5 = conservative)
  • Efficiency
    3Asset Turnover 0.24x (1.0+ = capital-efficient)
  • Growth
    0Insufficient data
  • Margin Trend
    0Op Margin -0.3% · trend -14.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project BLFS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$3.76
Total enterprise IV
$183M
Diluted shares
0.05B
Terminal PV
$133M (72% of total)
Year-5 FCF
$16M
YearProjected FCFDiscounted PV
+1$11M$10M
+2$12M$10M
+3$13M$10M
+4$14M$10M
+5$16M$10M
Terminal$214M$133M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$4M
investment in PP&E
Stock-based comp (TTM)
$23M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$406M
everything owned
Total liabilities
$34M
everything owed
Stockholders' equity
$372M
shareholder claim
Net debt
$-28M
Net cash position ($28M)

Recent performance · 64 quarters

Revenue
$19M
Net Income↑+136.5% +$2M
$621K
Free Cash Flow↓-49.1% -$807K
$838K
Operating Margin↑+1.6pts
-0.3%

Drill down

BLFS Sankey

See BioLife Solutions, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

BLFS Charts

64 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

BLFS Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics